Outlier Cancer Patient Responds to Everolimus in Sloan‑Kettering Trial
Outlier Cancer Patient Responds to Everolimus in Sloan‑Kettering Trial The passage describes a medical case study with no mention of political, financial, or intelligence actors. It offers limited investigative value beyond a potential follow‑up on a drug’s efficacy, which is already a known research area. Key insights: Patient #45 showed complete remission after everolimus despite overall trial failure.; Genomic analysis identified two mutations, one present in 8‑10% of bladder cancer cases.; Dr. David Solit, director of developmental therapeutics at Sloan‑Kettering, led the analysis.
Summary
Outlier Cancer Patient Responds to Everolimus in Sloan‑Kettering Trial The passage describes a medical case study with no mention of political, financial, or intelligence actors. It offers limited investigative value beyond a potential follow‑up on a drug’s efficacy, which is already a known research area. Key insights: Patient #45 showed complete remission after everolimus despite overall trial failure.; Genomic analysis identified two mutations, one present in 8‑10% of bladder cancer cases.; Dr. David Solit, director of developmental therapeutics at Sloan‑Kettering, led the analysis.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.